Transmission of Influenza Virus From Asymptomatic Healthcare Workers and Inpatients in the Acute Care Hospital Setting

Human Influenza Clinical Trial

— TransFLUas  

Official title:

TransFLUas: Transmission of Influenza Virus From Asymptomatic Healthcare Workers and Inpatients in the Acute Care Hospital Setting: A Prospective Study Over Two Consecutive Influenza Seasons

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02478905
• Other study ID #: KEK-ZH-Nr. 2015-0228
• Status: Completed
• Phase: N/A
• First received: June 5, 2015
• Last updated: October 30, 2017
• Start date: January 2016
• Est. completion date: June 2017

Study information

• Verified date: October 2017
• Source: University of Zurich
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The epidemiology and transmission dynamics of influenza in hospitals are only poorly understood, particularly with respect to subjects without symptoms of influenza infection (e.g. without fever, cough, sore throat, nasal congestion, weakness, headache, loss of appetite, or myalgia). Knowledge about whether asymptomatic subjects are able to transmit influenza is of major importance. If they do transmit influenza, vaccination of patients and healthcare workers (HCW) before start of the influenza season, the permanent use of masks by HCW during influenza season, and quarantine for previously exposed inpatients may be the only available measures to reduce the number of influenza transmission events from asymptomatic subjects in acute care hospitals. Closure of this knowledge gap would be of major benefit to infection prevention and control recommendations, and may in turn reduce morbidity and mortality associated with influenza in hospitals through improved patient management.

Description:

The epidemiology and transmission dynamics of influenza in hospitals are only poorly understood, particularly with respect to subjects without symptoms of influenza infection (e.g. without fever, cough, sore throat, nasal congestion, weakness, headache, loss of appetite, or myalgia). Knowledge about whether asymptomatic subjects are able to transmit influenza is of major importance. If they do transmit influenza, vaccination of patients and healthcare workers (HCW) before start of the influenza season, the permanent use of masks by HCW during influenza season, and quarantine for previously exposed inpatients may be the only available measures to reduce the number of influenza transmission events from asymptomatic subjects in acute care hospitals.

The investigators' key aim is therefore to define whether exposure to asymptomatic subjects with influenza infection constitutes a risk for influenza transmission in an acute care hospital setting through active, prospective surveillance.

The investigators' secondary aims are to describe the prevalence of community-acquired symptomatic and asymptomatic influenza upon hospital admission and the incidence of asymptomatic and symptomatic nosocomial influenza among inpatients; to assess transmission dynamics of symptomatic influenza infection in acute care; and to study the incidence of asymptomatic and symptomatic influenza, absenteeism (i.e. being absent from work due to influenza), presenteeism (i.e. being present at work despite influenza infection) associated with influenza, and compliance with infection control recommendations to prevent spread of influenza in acute care HCW.

The investigators plan to enroll 1,260 inpatients and 180 HCW from medical wards at the University Hospital Zurich in a prospective study over two consecutive influenza seasons in order to detect at least one transmission event from an asymptomatic individual shedding influenza virus. Flocked mid-turbinate nasal swabs will be collected daily from consenting inpatients starting from day of admission until two days after discharge and from HCW over the influenza (winter) season and analyzed for influenza A and B using polymerase chain reaction. Simultaneously, signs and symptoms of influenza infection (including cough, sore throat, fever >37.8°C, nasal congestion, weakness, headache, loss of appetite or myalgia) as well as contact patterns between inpatients and HCW will be recorded. Reconstruction of influenza transmission chains will be based on phylogenetic analyses derived from next-generation sequence data and epidemiological contact tracing.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 700
• Est. completion date: June 2017
• Est. primary completion date: June 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18 or more years of age;

• Available for follow-up during the study period;

• If a HCW: employed full- or part-time (=50% full-time equivalent);

• Understand the study, agree to its provisions, and give written informed consent (as documented by signature).

Exclusion Criteria:

• If a HCW: planning to spend more than two consecutive weeks outside of Switzerland during the winter study period (November 1st to April 31st);

• If a HCW: planning to take leave from work for more than two consecutive weeks during the winter study period (e.g. maternity or medical leave);

• Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders or dementia of the subject;

• Known or suspected non-compliance.

Related Conditions & MeSH terms

• Human Influenza
• Influenza, Human

Intervention

Other:
• Influenza

Locations

Country	Name	City	State
Switzerland	University Hospital Zurich	Zurich

Sponsors (2)

Lead Sponsor	Collaborator
University of Zurich	Schweizerischer Nationalfonds

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Secondary attack rate of asymptomatic or presymptomatic influenza among inpatients, among acute care workers and between inpatients and acute care HCW in an acute care hospital setting	diagnosed by positive influenza PCR from flocked mid-turbinate nasal swab collected in symptomatic or asymptomatic individuals following face-to-face contact with an individual with symptomatic influenza infection on the day of contact.	up to 6 months
Secondary	Secondary attack rate of symptomatic influenza among inpatients, among acute care workers and between inpatients and acute care HCW in an acute care hospital setting	Secondary attack rate of symptomatic influenza among inpatients, among acute care workers and between inpatients and acute care HCW in an acute care hospital setting: as diagnosed by positive influenza PCR from flocked mid-turbinate nasal swab collected in symptomatic or asymptomatic individuals following face-to-face contact with an individual with symptomatic influenza infection on the day of contact. Transmissions will be considered 'proven' if confirmed by phylogenetic analyses. Specifically, we expect that whole-genome sequence analysis will demonstrate identical or almost identical influenza strains within transmission chains.; Transmissions will be considered 'probable' if there is epidemiological evidence of face-to-face contact and identical strains have been identified in PCR but whole-genome sequencing was technically unsuccessful;	up to 6 months
Secondary	Proportion of asymptomatic and symptomatic inpatients with influenza infection upon hospital admission: as diagnosed by influenza polymerase chain reaction (PCR) from flocked mid-turbinate nasal swabs collected upon hospital admission	diagnosed by influenza PCR from flocked mid-turbinate nasal swabs collected upon hospital admission	up to 6 months
Secondary	Incidence of asymptomatic (A5) and symptomatic (A6) nosocomial influenza in hospital inpatients, defined as the number of emerging influenza infections >72 hours after hospital admissions per 100 patient-days	diagnosed by PCR from flocked mid-turbinate nasal swabs collected three times per week over the influenza season	up to 6 months
Secondary	Incidence of asymptomatic (A7) and symptomatic (A8) influenza in acute care hospital workers defined as the number of influenza infections per 100 HCW per influenza season	diagnosed by influenza PCR from flocked mid-turbinate nasal swabs collected three times per week over the influenza season collected three times per week over the influenza season	up to 6 months
Secondary	Association of individual influenza symptoms with influenza transmission from subjects with symptomatic influenza infection	Association of individual influenza symptoms with influenza transmission from subjects with symptomatic influenza infection	up to 6 months
Secondary	Influenza-attributable mortality in inpatients, expressed as infection-fatality rate, i.e. number of deaths among those infected	number of deaths among those infected	up to 6 months
Secondary	Absenteeism: as defined by total number of days absent from work due to PCR-proven influenza divided by total number of days due to work in HCW	Absenteeism: as defined by total number of days absent from work due to PCR-proven influenza divided by total number of days due to work in HCW;	up to 6 months
Secondary	Presenteeism: as defined by total number of days with symptoms of influenza present at work divided by total number of days due to work in HCW with PCR-proven influenza infection	Presenteeism: as defined by total number of days with symptoms of influenza present at work divided by total number of days due to work in HCW with PCR-proven influenza infection;	up to 6 months
Secondary	Compliance with hand hygiene recommendations and cough etiquette (including barrier precautions) in HCW according to repeated observations	Compliance with hand hygiene recommendations and cough etiquette (including barrier precautions) in HCW according to repeated observations;	up to 6 months
Secondary	Association of patient and HCW characteristics, including receipt of influenza vaccine, with asymptomatic viral shedding, as compared to symptomatic shedding	Association of patient and HCW characteristics, including receipt of influenza vaccine, with asymptomatic viral shedding, as compared to symptomatic shedding;	up to 6 months
Secondary	Association between viral load and asymptomatic or symptomatic transmission based on quantification of viral shedding according to cycle threshold (Ct) values from PCR	defined as the number of cycles required for the fluorescent signal to cross the threshold (i.e. exceeds background level).	up to 6 months